Scholar Rock Holding Corp
Company Stats
- Market Cap
- $5.9B
- as of Sep 30, 2026
- Shares Outstanding
- 121.8M
- Free Float
- 72.0%
Income Statement
- Revenue
- $0
- Operating Income
- -$384.6M
- Net Income
- -$377.9M
- EBITDA
- -$383.0M
Cash Flow
- Free Cash Flow
- -$300.6M
- FCF Yield
- -5.1%
- Owner FCF Yield
- -6.4%
Balance Sheet
- Cash & Equivalents
- $323.5M
Returns & Capital
- SBC, 3Y Avg
- $46.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$300.6M | — |
| FY2024 | — | -$201.0M | — |
| FY2023 | — | -$145.3M | — |
| FY2022 | $33.2M | -$133.8M | -403.0% |
| FY2021 | $18.8M | -$132.0M | -701.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
November 2, 2026
Insider Signal
Rapport buying stands out relative to size; Beacon brings breadth
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 21, 2026
FDA
FDA Approves Scholar Rock's ISEMBYLD
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
Rapport buying stands out relative to size; Beacon brings breadth
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 21, 2026
FDA
FDA Approves Scholar Rock's ISEMBYLD
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back